Incyclix Bio in Clinical Trial Collaboration and Supply Agreement with Lilly

 INX-315, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio® (abemaciclib) and fulvestrant

Combination therapy to be evaluated as part of ongoing Phase 1/2 study in patients with HR+/HER2- metastatic breast cancer

Incyclix will sponsor the trial and Lilly will provide Verzenio

Incyclix plans to initiate combination cohorts with INX-315 in fourth quarter of 2024

https://www.biospace.com/press-releases/incyclix-bio-announces-clinical-trial-collaboration-and-supply-agreement-with-lilly-to-evaluate-inx-315-in-combination-with-verzenio-abemaciclib-and-fulvestrant-in-hr-her2-breast-cancer